Key result
Rivaroxaban provides a stable and predictable anticoagulant effect for the treatment of thromboembolism and atrial fibrillation without the need for routine laboratory monitoring.
Why the study?
Does a personalized approach with rivaroxaban prevent thromboembolism and bleeding in patients with atrial fibrillation or pulmonary embolism?
Does a personalized approach with rivaroxaban prevent thromboembolism and bleeding in patients with atrial fibrillation or pulmonary embolism?
Rivaroxaban can be safely and effectively used in a personalized approach for patients with atrial fibrillation and pulmonary embolism, including those who received prior thrombolytic therapy.
Supports personalized rivaroxaban in select AF/PE cases; hypothesis-generating and should not yet change practice.
No takes yet. Share an insight, caveat, or question.
Delić et al. (2015) conducted a review in Atrial fibrillation, pulmonary embolism, venous thromboembolism. Rivaroxaban vs. Vitamin K antagonists (Warfarin) or Enoxaparin was evaluated. Rivaroxaban provides a stable and predictable anticoagulant effect for the treatment of thromboembolism and atrial fibrillation without the need for routine laboratory monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: